BioTime research report agenda
I just made 1,4% on BioTime Inc. today, could have made more but I think that BioTime Inc. will grow substantially over the next decades. BioTime technology is next generation technology, that is much safer than what Geron has. I think it is the #1 company in stem cells/ regenerative medicine globally as of today that is best positioned to cure cancer, heart disease, neurodegenerative diseases and ageing as a regulation disease. CEO is brilliant, one of the founders of stem cell industry. Since Mike West joined the company as a CEO in 2007 BioTime has grown from $0.20 per share to amazing $8.9 per share and capitalization of $ 424.56M. One of the leading investors in BioTime is BlackRock with US$3.45 trillion assets under management. BioTime started successfully working with China as of last year: BioTime Inks Progenitor Cell Distribution Deal for China at Seeking Alpha Sun, Dec 12
Just this year alone the company should complete many more deals.
BioTime, Inc. Common Stock (AMEX: BTX )
After Hours: 8.92 0.00 (0.00%) 5:42PM EST
Last Trade:8.92
Trade Time:4:01PM EST
Change: 0.59 (7.08%)
Prev Close:8.33
Open:8.36
Bid:8.10 x 200
Ask:9.50 x 5000
1y Target Est:N/A
Day's Range:8.36 - 9.09
52wk Range:4.02 - 9.94
Volume:366,149
Avg Vol (3m):255,641
Market Cap:424.56M
P/E (ttm):N/A
EPS (ttm):-0.18
Div & Yield:N/A (N/A)
Headlines
BioTime Subsidiary ReCyte Therapeutics, Inc. to Develop Therapies for Age-Related Cardiovascular and Blood Disorders Business Wire Mon 9:00AM EST
BIOTIME INC Files SEC form 8-K, Unregistered Sale of Equity Securities, Other Events EDGAR Online Mon 8:45AM EST
The End-of-Year Melt Up Continues Indie Research Wed, Dec 29
BioTime, Inc. and the University of California System Sign Cell Transfer Agreement for Human Embryonic Stem Cell Lines Business Wire Wed, Dec 22
Director Of Equity Research At RBC Capital Markets Covers Phase III Data For Multiple New Drugs; Find Out The Stocks That Investors Should Look At Wall Street Transcript Fri, Dec 17
Breakout Stocks Chased by Smart Money at Seeking Alpha Mon, Dec 13
China Biotech Week in Review: GSK Acquires Urology Drugmaker at Seeking Alpha Sun, Dec 12
BioTime Inks Progenitor Cell Distribution Deal for China at Seeking Alpha Sun, Dec 12
BIOTIME INC Files SEC form 8-K, Other Events EDGAR Online Thu, Dec 9
BioTime Asia, Limited and Shanghai Genext Medical Technology Co., Ltd. Sign Marketing Agreement for ACTCellerate™ Cell Lines Business Wire Thu, Dec 9
I hope you find this as interesting as I do.
We are currently looking for the leading life sciences / stem cells analyst on the market to write a research report on BioTime Inc. Please contact me at my private e-mail: y.oreshin@gmail.com
Kind regards,
Yury Oreshin
Partner
Teknoinvest Angelico Ventures
9-105 Esseninsky boulevard
Moscow, Russia 109439
Cell: +79163888355 (Moscow)
Tel: +442032879882 (London)
y.oreshin@angelicobiotech.com
www.angelicobiotech.com
Disclosure: I am long OTC:BTIM, OTC:BTIM.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.